Under our immuno-oncology collaboration with TESARO, we have granted exclusive rights to TESARO to develop and commercialize the following AnaptysBio-generated antibody product candidates:
- Anti-PD-1 Monospecific Antagonist Antibody (TSR-042): Registration program initiated for metastatic microsatellite instability high (MSI-H) endometrial cancer in Q2 2017;
- Anti-TIM-3 Monospecific Antagonist Antibody (TSR-022): Dose escalation completed in Phase 1, combination trial with TSR-042 has been initiated;
- Anti-LAG-3 Monospecific Antagonist Antibody (TSR-033): Phase 1 trial initiated, and
- Anti-PD-1/LAG-3 Bispecific Antagonist Antibody (TSR-075): lead candidate identified, IND-enabling studies on-going.
To access scientific publications on this topic, please click here.
Under our collaboration with Celgene, we developed therapeutic antibodies against multiple targets. We granted Celgene the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under collaboration. Celgene is currently advancing two AnaptysBio-generated anti-inflammatory antibody programs, and has initiated a Phase 1 trial for one of these two antibodies known as CC-90006, a PD-1 agonist antibody, which is indicated for psoriasis.